A Colorimetric Test to Differentiate Patients Infected with Influenza from COVID‐19
| Autor: | Natalie G Bell, Mohamed A. Abdou Mohamed, Kyryl Zagorovsky, Samira Mubareka, Jisung Kim, Warren C. W. Chan, Hannah N Kozlowski |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
2019-20 coronavirus outbreak
Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viruses 02 engineering and technology 010402 general chemistry 01 natural sciences Virus colorimetric diagnostics Medicine Research Articles business.industry fungi gold nanoparticles influenza A Clinical performance virus diseases Influenza a 021001 nanoscience & nanotechnology Virology 3. Good health 0104 chemical sciences DNAzymes Viral genomes respiratory infections SARS‐CoV‐2 0210 nano-technology business Research Article |
| Zdroj: | Small Structures |
| ISSN: | 2688-4062 |
| Popis: | Patients infected with SARS‐CoV‐2 and influenza display similar symptoms, but treatment requirements are different. Clinicians need to accurately distinguish SARS‐CoV‐2 from influenza to provide appropriate treatment. Here, the authors develope a color‐based technique to differentiate between patients infected with SARS‐CoV‐2 and influenza A using a nucleic acid enzyme‐gold nanoparticle (GNP) molecular test requiring minimal equipment. The MNAzyme and GNP probes are designed to be robust to viral mutations. Conserved regions of the viral genomes are targeted, and two MNAzymes are created for each virus. The ability of the system to distinguish between SARS‐CoV‐2 and influenza A using 79 patient samples is tested. When detecting SARS‐CoV‐2 positive patients, the clinical sensitivity is 90%, and the specificity is 100%. When detecting influenza A, the clinical sensitivity and specificity are 93% and 100%, respectively. The high clinical performance of the MNAzyme‐GNP assay shows that it can be used to help clinicians choose effective treatments. Molecular diagnostic tests are needed to differentiate patients infected with COVID‐19 and influenza to guide treatment decisions. A colorimetric test using nucleic acid enzymes and gold nanoparticles is developed to identify these respiratory pathogens. The test has 93–95% sensitivity and 100% specificity in patients. The results support rapid translation of this materials‐based diagnostic approach for use in human patients.© 2021 WILEY‐VCH GmbHThis article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|